Zdrowie i gospodarka · 12/08/2026
NIH-Owned Invention Available for License: Drug-Regulatable, Inducible Expression of Membrane-Bound Interleukin 12 (DRIM-IL-12) for Use in Adoptive Cell Therapy
The National Cancer Institute (NCI) is seeking partners to advance a novel, tightly regulated cytokine platform that enhances anti-tumor efficacy in adoptive cell therapy, while improving safety, and is available for license.